Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
06. März 2023 04:00 ET
|
AKAMPION
Expanded partnership of two leading innovatorsResomer® used in commercial 3D-printed implants for both soft and hard tissue applicationsBellaSeno receives market authorization for fully resorbable...
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
23. Februar 2023 04:00 ET
|
AKAMPION
- Leading European T cell therapy researcher adds further scientific expertise ROTTERDAM, February 23, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery...
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
25. Januar 2023 04:00 ET
|
AKAMPION
- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17. Januar 2023 04:00 ET
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
17. Januar 2023 04:00 ET
|
AKAMPION
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
13. Dezember 2022 04:00 ET
|
AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
29. November 2022 04:00 ET
|
AKAMPION
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
23. November 2022 04:00 ET
|
AKAMPION
- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
16. November 2022 04:00 ET
|
AKAMPION
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 --- Dopavision, a...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15. November 2022 04:00 ET
|
AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors - Potential as mono- and combination therapy for...